炎症药物开发解决方案

Leveraging integrated medical, operational and commercial approaches for inflammation study success

  • 识别新型药剂,用于治疗具有普通途径的多种炎症性疾病

  • 通过有效的试验设计和端点评估确保强大和有意义的数据

  • Engage in effective partnerships that facilitate movement of therapies through the clinical development life cycle

您的需求

目前对许多器官,系统和疾病共享的炎症性失调的理解意味着单一器官的症状浮雕不足。利用更全面的炎症药物发育方法是关键,解决免疫激活和控制之间的不平衡。

通过这样做,您靶向疾病修改而不是症状缓解,这具有巨大的未来影响,与80多种慢性免疫介导的炎症疾病(IMID)共享类似的分子途径。

利用我们的科学专业知识和经验将炎症疗法带到市场,使您能够延长覆盖范围并为更多患者带来利益。

C034/5673

炎症性疾病的相互关联性质在炎症研究中产生了复杂性,同时也为成功治疗剂投资高回报的机会。

对于这种战略方法,您需要一个可以在多种炎症性疾病中筛选新型药物的单一合作伙伴。Covance提供广泛的临床前和临床专业知识,以帮助识别和推进您的新型药剂,无论是新的化学实体(NCE),生物,生物仿制性还是干细胞。

测试呼吸功能

Progressing your new therapy into trials requires you to find the right patients and the most suitable sites, which are often found all over the world. To support your global study plan, you need a partner with a global footprint.

At any one time, Covance Central Laboratory Services is working on over 40% of clinical trials worldwide. Insights gained from the data collected, which is housed in a central knowledgebase, allow us to strategically address your clinical trial needs. Leverage Covance and LabCorp data by usingXcellate.®试验设计to pressure test trial protocols, identify optimal sites and target specific patient populations. Our worldwide pool of expertise allows centralized assessment of trial endpoints and ongoing test results, wherever your trial sites are, yielding consistent analyses and data you can rely on.

我们的能力

在竞争性和复杂的疾病景观中取得成功需要深入了解您的特定治疗区域,生物标志物鉴定和验证的专业知识,目前的监管环境,以及在某些情况下,生物仿制性的发展。

自2012年以来,Covance在类风湿性关节炎(IV期)进行了190项。2015年前三大畅销的类风湿性关节炎药物与Covance合作,涉及首次销售的抗IL-6产品的发展。我们的代表专业监管团队始终如一地支持我们将炎症治疗带来炎症治疗的经验。每个团队成员最多30年来处理全球全球和当地机构的经验。

508351346

Underpinning the success of drugs developed with Covance is our longstanding expertise in the identification, development and validation of biomarkers. Access our world-leading global central laboratory capabilities, where we have over 4,800 tests, including a comprehensive range of standard and specialist inflammatory biomarker assays, such as the eosinophil cationic protein test.

炎症性疾病研究需要与具有广泛科学专业知识的CRO合作。我们的专业科学和运营团队定位为帮助您的产品从概念转移到商业化,促进开发阶段之间的过渡。

Covance具有14个炎症免疫介导的炎症疾病(IMID)药物中的14种,并且擅长为您的治疗提供必要的工具,以实现炎症性疾病领域的成功。

我们的专有Xcellate.®信息学套房利用患者数据来帮助您提出明智的临床试验决策。Xcellerate试验设计将我们的诊断和疾病数据与我们的全球调查员历史性能数据库结合起来。这使我们能够根据目标患者池的位置和试验调查人员的排名推荐最佳学习网站。亚博全站官网XCellerate试验设计也可用于压力测试协议,以最大限度地确定入门标准之前最大化患者可用性。

Our other Xcellerate informatics solutions can increase operational efficiencies across all aspects of your trial, covering processes such as trial management and site performance monitoring while reducing risks through independent data review and near-real-time quantification of adverse events and protocol deviations. Using these advanced analytical solutions, trial timelines can be reduced by up to seven months and costs reduced by millions of dollars.